Status and phase
Conditions
Treatments
About
Primary Objective:
Secondary Objective:
Study Duration:
Twelve months for each patient
Study Treatment: Ciclosporine
Group A: low dose >= 130 µg/l < T0 ciclosporinemia < 200 µg/l; Group B: standard dose >= 200 µg/l < T0 ciclosporinemia < 300 µg/l.
Study Visits:
One visit every 15 days, for the first three months; then 1 visit every month, for 6 months; and 1 visit at 9 and 12 months.
Associated Treatments:
Randomization: Randomization will occur when it is decided that ciclosporine will be introduced.
Sex
Ages
Volunteers
Inclusion criteria
Recipient:
Donor:
Exclusion criteria
Recipient:
Donor:
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal